TOKYO, Apr 01 (Pulse News Wire) – Shionogi & CO.,LTD. (4507.T) completed its investment in British pharmaceutical firm ViiV Healthcare Ltd.
On January 20, 2026. As part of this transaction, Shionogi invested an additional amount of $2.125 billion and received new shares from ViiV Healthcare, increasing its stake to 21.7%. This move elevates ViiV Healthcare to a jointly controlled affiliate company, with Shionogi holding a voting rights ratio of 11.7%.
Shionogi identifies addressing the threat of infectious diseases as a key priority, particularly focusing on HIV and other major infections. By deepening its partnership with ViiV Healthcare and GlaxoSmithKline (GSK), Shionogi aims to further contribute to global HIV treatment and prevention efforts, responding to unmet needs of those living with HIV. This strategic investment underscores Shionogi's commitment to advancing healthcare solutions for infectious diseases, reinforcing its position in the field of HIV research and development.
🟢 Confidence: High AI-translated content.